EU approves first gene therapy for hemophilia B 21-Feb-2023 By Jonathan Smith Three months after receiving the US green light, CSL’s candidate Hemgenix has become the first gene therapy to gain EU approval for the treatment of hemophilia B.
FDA approves first gene therapy for hemophilia B 24-Nov-2022 By Rachel Arthur CSL’s Hemgenix (etranacogene dezaparvovec-drlb) becomes the first treatment to offer patients freedom from regular ongoing infusions.
CSL inaugurates new R&D center in Germany 15-Sep-2022 By Rachel Arthur The €150m ($150m) new facility will become CSL’s largest R&D site: with more than 500 employees and a multitude of disciplines.
Building a biotech hub: Switzerland puts the focus on personalized medicine, mRNA, CGT and more 08-Sep-2021 By Rachel Arthur Switzerland wants to build on the momentum of recent years to get ahead in key areas for the future.
CSL Behring in $450m spend on hemophilia gene therapy 30-Jun-2020 By Ben Hargreaves The company buys the global rights to a gene therapy currently going through Phase III trials.
